NYSE · Health Care · Pharmaceuticals
LLY Eli Lilly and Company
As of 2026-05-20 · Indianapolis, IN
Business summary
Eli Lilly is the leader in the metabolic / cardiometabolic franchise that has emerged as one of the largest single drug categories ever. Tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) is GLP-1/GIP agonism with materially better weight-loss efficacy than Novo's semaglutide; orforglipron (oral, branded Foundayo) is the next leg, approved in 2026, expanding the addressable market by collapsing the injection-friction barrier. Beyond obesity/diabetes, Lilly has commercial assets in oncology (Verzenio), immunology (Taltz), and Alzheimer's (Kisunla / donanemab).
The operational story is manufacturing. Demand has consistently outrun supply for tirzepatide, and Lilly's $4.2B+ in announced capacity expansion ($3B Netherlands + $1.2B Puerto Rico, both for orals) is the right move to capture the oral wave. Medicare access for Zepbound from July 1, 2026 broadens the payer base materially. Risks include competitive new entrants (Pfizer's danuglipron, Roche/Carmot's CT-388, Novo's CagriSema, Lilly's own retatrutide), real-world adherence below trial data on orals, and any unexpected safety signal that hits the whole category.
Connected theses
- T003 — Oral GLP-1s expand the obesity drug market by an order of magnitude, and Lilly's manufacturing lead compounds · core
Single-name expression of the oral GLP-1 mass-market thesis. Best operator + best pipeline.
Key metrics
| Tirzepatide franchise revenue (FY25) | >$30B (estimated) Mounjaro + Zepbound combined. | FY2025 |
|---|---|---|
| Manufacturing capex (announced) | $4.2B+ in oral manufacturing $3B Netherlands + $1.2B Puerto Rico. | 2026 |
| Medicare access for Zepbound | Effective July 1, 2026 Material payer broadening. | 2026 |
Valuation snapshot
| Price | $988.09 |
|---|---|
| Market cap | $940B |
| Forward P/E | 32.0× |
| EV / EBITDA | 22.0× |
| FCF yield | 2.4% |
Premium multiple reflects franchise dominance + pipeline. Down materially from 2024 peaks; reasonable risk/reward at current levels.
Evidence
- secondary Lilly Q1 2026 results + capex expansionQ1 results + $4.2B oral manufacturing capex announcements + Medicare access effective July.
- Positive Phase 3 results for orforglipron in switchers from injectable GLP-1; combo therapy data for psoriasis + obesity.
- Multiple orals + combos advancing across Lilly + Novo + Pfizer + Roche pipelines.
Catalysts
- Q2 2026 earnings — first quarter of Medicare access high
What to watch: Tirzepatide volumes, orforglipron launch trajectory, payer mix - Retatrutide Phase 3 readouts high
What to watch: Next-gen Lilly molecule; data dictates competitive positioning vs CagriSema
Falsifiers
- Orforglipron real-world adherence/efficacy materially below trial data after launch
armed · Real-world data + payer formulary reactions - Payer coverage rollback OR Medicare formulary exclusion
armed · CMS rulings, PBM negotiations - Manufacturing yield issue persists 2+ quarters
armed · Earnings commentary on supply - New entrant with materially better profile (e.g., amycretin Phase 3 readout) closer than expected
armed · Clinical trial readouts
Agent notes
Hold. Lilly is the best operator in the most important new drug category in a decade. Medicare access in July is a near-term catalyst; orforglipron real-world performance is the dominant 12-month variable. Sized appropriately at ~8%.
Educational notes
📚 GLP-1 mechanism + oral barrier
GLP-1 (glucagon-like peptide-1) is a gut hormone that, when activated, reduces appetite and slows gastric emptying. The natural hormone is rapidly degraded — that's why early GLP-1 drugs (semaglutide, tirzepatide) are weekly injections of long-half-life synthetic versions. Oral formulations are scientifically hard because peptide drugs get destroyed by stomach acid. Novo's oral semaglutide uses a special permeation enhancer (SNAC); Lilly's orforglipron is a non-peptide small molecule that mimics GLP-1 — different chemistry, easier oral delivery. Oral matters because adherence drops dramatically with injections — people who need weekly injections often discontinue within a year. Oral expands the practical market 5-10×.
Open questions
- Run-rate orforglipron pricing vs payer pushback?
- Retatrutide readout date?
- How much of supply constraint is real vs strategic allocation?